Corporate Governance
Burjeel Holdings is committed to the highest levels of governance. In 2022 we appointed a Board of Directors with significant international industry and governance experience to help guide us through our next phase of expansion. Our Board of Directors is supported by an Audit Committee, a Nomination and Remuneration Committee and a Clinical and Medical Advisory Committee. The Company is led by a high quality senior management team with a wealth of industry experience.
The Clinical and Medical Advisory Committee provides support and advice to the Board in relation to programs for clinical pathways, the standardisation of care, the identification of best-practice standards, quality and patient safety related KPIs and quality improvement programs. It supports and advises on training, mentoring and development, and provides a connection to, and ongoing exchange of information and ideas with, practitioners in the field and other external contacts.
Across all our brands and businesses, we have implemented effective and transparent governance frameworks, in line with best in class standards and regulatory requirements.
Corporate Governance and Compliance
- Information Security Policy
- Insider Trading Policy
- Investor Relations Policy
- Policy of the Policies
- Related Party Transactions Policy
- Sanctions and Trade Control Policy
- Whistleblower Policy
- Anti-Money Laundering Policy
- Code Conduct
- Conflict Of Interest Policy
- Data Privacy Policy
- External Audit Policy
- Governance and Board Composition Policy
- Whistleblower Policy
Leadership Team
Board Committees
The Board has established two permanent committees – an Audit Committee and a Nomination and Remuneration Committee, both in adherence with the composition requirements of the SCA Governance Rules. In accordance with the SCA Governance Rules, the Chairperson is not permitted to be a member of either the Audit Committee or the Nomination and Remuneration Committee. A high-level overview of the mandate of each of these committees, as at listing upon ADX, is set out below.
The Audit Committee assists the Board in discharging its responsibilities relating to financial reporting, external and internal audits and controls, including reviewing and monitoring the integrity of the financial statements, reviewing and monitoring the extent of the non-audit work undertaken by external auditors, advising on the appointment of external auditors, overseeing the relationship with the external auditors, reviewing the effectiveness of the external audit process, and reviewing the effectiveness of the internal control review function. The ultimate responsibility for reviewing and approving the annual report and accounts remains with the Board. The Audit Committee gives due consideration to the applicable laws and regulations of the UAE, the ADGM, the SCA and the ADX. The Audit Committee meets at least once every three months or as required.
The Nomination and Remuneration Committee assists the Board in setting and overseeing the nomination and remuneration policies in respect of the Board, any committees of the Board and senior management. In such capacity, it is responsible for evaluating the hiring of the Company’s executive management, evaluating the balance of skills, knowledge and experience of the Board and committees of the Board and, in particular, monitoring the independent status of the independent Directors. It is also responsible for periodically reviewing the Board’s structure and identifying, where relevant, potential independent candidates to be appointed as Directors or committee members as the need may arise. In addition, and subject to the Articles of Association, the Nomination and Remuneration Committee assists the Board in determining its responsibilities in relation to remuneration, including making recommendations to the Board on the Company’s policy on executive remuneration, setting the overarching principles, parameters and governance framework of the remuneration policy and determining the individual remuneration and benefits package of the senior management.
The Clinical and Medical Advisory Committee provides support and advice to the Board in relation to programs for clinical pathways, the standardisation of care, the identification of best-practice standards, quality and patient safety related KPIs and quality improvement programs. It also supports and advises on training, mentoring and development, and provides a connection to, and ongoing exchange of information and ideas with, practitioners in the field and other external contacts.
The Business Development Committee provides support and advice to the Board in relation to business development plans, international expansion and revenue growth. It also supports and advises the Board on marketing and positioning strategies.
